MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
1.925
-0.075
-3.75%
Opening 15:20 05/18 EDT
OPEN
2.030
PREV CLOSE
2.000
HIGH
2.060
LOW
1.900
VOLUME
4.59M
TURNOVER
--
52 WEEK HIGH
4.460
52 WEEK LOW
0.8621
MARKET CAP
664.17M
P/E (TTM)
-2.5059
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALLO last week (0511-0515)?
Weekly Report · 14h ago
Allogene Therapeutics Balances Bold Data With Rising Spend
TipRanks · 4d ago
Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors
TipRanks · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Allogene Therapeutics (ALLO)
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Biogen (BIIB) and COMPASS Pathways (CMPS)
TipRanks · 4d ago
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M
Seeking Alpha · 4d ago
Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)
TipRanks · 4d ago
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)
TipRanks · 4d ago
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.